Slow-release theophylline or Montelukast respectively combined with inhaled budesonide in the treatment of children with cough variant asthma: Comparative study

Objective To evaluate the efficacy and safety of slow-release theophylline(SRT) or Montelukast respectively combined with inhaled budesonide in the treatment of children with cough variant asthma(CVA).Methods The 85 CVA patients aged 5-13-years-old were randomly divided into two groups: A group,SRT 5 mg/kg·d,oral administration of 1 per morning and evening;B group,Montelukast 10 mg,oral administration of 1 per evening.A group and B group all daily inhaled budesonide 400 μg,morning and evening,for 12 weeks full.After the treatment,outcomes to be observed included the time of cough disappearance and the case of cough disappearance in each group,PEF measured value/expected value and the PEF variation rate per day,the incidence of adverse events.All well as,follow-up of 3 months after treatment,the recurrence rate of two groups were compared each other.Results In the treatment of 4 weeks,the time of cough disappearance and the case number of cough disappearance,and in the treatment of 12 weeks the lung function(PEF) improvement rate,as well the recurrence rate after treatment were no significant difference between A group and B group(P0.05).Conclusion SRT and Montelukast respectively combined with inhaled budesonide were used in the treatment of children with CVA show significant efficacy and safety,there are no significant different between A group and B group(P0.05).